AMGN

Amgen
D

AMGN

Arincen67/100B

Amgen return on equity (ROE)

Amgen's return on equity is 65.43%: net income of 9.39B USD over the last twelve months on shareholders' equity of 14.35B USD.

Today
65.43%
Average, 5 years
132.41%
Low, 5 years
52.83%
High, 5 years
624.78%

ROE (return on equity) = net income (last 12 months) ÷ shareholders' equity = 9.39B ÷ 14.35B = 65.43%

ROE (return on equity)
Net income
Shareholders' equity

Each quarter's net income over its last four quarters, over the shareholders' equity at the quarter end.

Why is Amgen's return on equity so high?

Net margin
21.0%
profit on each dollar of sales
Asset turnover
0.41×
sales on each dollar of assets
Equity multiplier
10.46×
assets on each dollar of equity
Return on equity
89.1%
FY2025
  • FY202521.0% × 0.41 × 10.46 = 89.1%
  • FY202412.2% × 0.36 × 15.63 = 69.6%
  • FY202323.8% × 0.29 × 15.59 = 107.8%
  • FY202224.9% × 0.40 × 17.79 = 179.0%
  • FY202122.7% × 0.42 × 9.13 = 88.0%

The DuPont breakdown, on each year-end's assets and equity, as the return on equity elsewhere on this page. A high equity multiplier means a small equity base: debt, or buybacks that return the equity to shareholders, lift the return on what is left.

ROE (return on equity) by year and by quarter

Fiscal yearPeriod endingROE (return on equity)Net incomeShareholders' equity
Today65.43%9.39B14.35B
FY202531 Dec 202589.06%7.71B8.66B
FY202431 Dec 202469.59%4.09B5.88B
FY202331 Dec 2023107.78%6.72B6.23B
FY202231 Dec 2022178.97%6.55B3.66B
FY202131 Dec 202187.96%5.89B6.70B
FY202031 Dec 202077.20%7.26B9.41B
FY201931 Dec 201981.07%7.84B9.67B
FY201831 Dec 201867.15%8.39B12.50B
FY201731 Dec 20177.84%1.98B25.24B
FY201631 Dec 201625.85%7.72B29.88B
FY201531 Dec 201524.71%6.94B28.08B
FY201431 Dec 201420.01%5.16B25.78B
FY201331 Dec 201323.00%5.08B22.10B
FY201231 Dec 201222.80%4.35B19.06B
FY201131 Dec 201119.35%3.68B19.03B
FY201031 Dec 201019.32%4.63B23.94B
FY200931 Dec 200920.32%4.61B22.67B
FY200831 Dec 200820.58%4.20B20.39B
FY200731 Dec 200717.72%3.17B17.87B
FY200631 Dec 200615.56%2.95B18.96B
FY200531 Dec 200517.96%3.67B20.45B
FY200431 Dec 200411.99%2.36B19.71B
FY200331 Dec 200311.65%2.26B19.39B
FY200231 Dec 2002-7.61%-1.39B18.29B
FY200131 Dec 200121.46%1.12B5.22B
FY200031 Dec 200026.39%1.14B4.31B
FY199931 Dec 199936.26%1.10B3.02B
FY199831 Dec 199833.69%863.20M2.56B
FY199731 Dec 199730.12%644.30M2.14B
FY199631 Dec 199635.66%679.80M1.91B
FY199531 Dec 199532.16%537.70M1.67B
FY199431 Dec 199425.09%319.70M1.27B
FY199331 Dec 199331.96%374.60M1.17B
FY199231 Dec 199238.30%357.60M933.70M
FY199131 Dec 199118.43%97.90M531.10M
FY199031 Dec 19908.62%34.30M398.00M
FY198931 Dec 1989—19.10M—
FY198831 Dec 1988-5.06%-8.20M161.90M
FY198731 Dec 1987—1.70M—
FY198631 Dec 1986—800.00K—
FY198531 Dec 1985—500.00K—

Figures in USD. A quarter's revenue, net income and dividends are those of its last four quarters.

See also:P/E ratio,Market cap,P/S ratio,Dividend yield,Debt to equity,Current ratio,All ratios

Common questions about Amgen's ROE

Source: Financial Modeling PrepVerified against SEC filings